NCT00174486已完成2 期
A Double Blind, Placebo Controlled, Parallel Group, Multicenter Study To Assess The Duration Of Action, Safety And Toleration Of Differing Doses and Combinations Of Immediate and Modified Release Formulations Of UK-369,003 and Cialis Compared To Placebo In Adult Male Subjects With Erectile Dysfunction
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 300
- 主要终点
- Assessment of duration of action, safety & toleration of the investigational drug and Cialis
研究概览
简要总结
Assessment of duration of action, safety & toleration of different formulations and doses of UK-369,003 and Cialis in patients with male erectile dysfunction. Patients should have previously been on PDE5 inhibitors and have been respondents to the drug. Duration of treatment is 4 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Erectile Dysfunction
排除标准
- •Alpha blockers and Nitrates of any preparation
结局指标
主要结局
Assessment of duration of action, safety & toleration of the investigational drug and Cialis
次要结局
- Assess safety & toleration over 4 week treatment period
研究者
相似试验
已完成
2 期
Assessment of Onset, Safety & Toleration of UK-369,003 in Male Erectile DysfunctionImpotenceNCT00141349Pfizer300
已完成
2 期
Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency VirusHIV InfectionsNCT00643643ViiV Healthcare41
已完成
2 期
Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.Prostatic HyperplasiaNCT00457457Pfizer609
已完成
1 期
Investigate Safety, Tolerability, PK/PK of J2H 1702 in Healthy MalesNon-alcoholic SteatohepatitisNCT06308861J2H Biotech100
已完成
1 期
A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose LevelsPhase 1BioavailabilityHealthy SubjectsNCT02010944Astellas Pharma Europe B.V.72